📬 GYN Oncology Intelligence Digest — Week 2026-W38

KEYLYNK-001 reports a positive PFS result for pembrolizumab plus olaparib maintenance in BRCA non-mutated advanced ovarian cancer without an OS gain, while 5-year KEYNOTE-826 data confirm durable survival benefit in advanced cervical cancer, and NICE issues a technology appraisal for durvalumab with chemotherapy then olaparib in endometrial cancer.

⚡ TL;DR

📄 Publications

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. — 1367 patients were randomly assigned to pembrolizumab-olaparib (n=455), pembrolizumab (n=458), or control (n=454)
Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial. — 617 female patients were randomized; median follow-up for this analysis was 59.1 months (range 52.1-66.5)

🐦 Twitter / 🦋 Bluesky

KEYNOTE-826 5-year analysis: pembrolizumab plus chemotherapy holds its survival curve separation in advanced cervical cancer — At ~5 years in PD-L1 CPS >=1, 5-year OS was 33.9% vs 19.7%, median OS 28.6 vs 16.5 months, HR 0.62, and 5-year PFS 27.3% vs 9.9% with HR 0.58
KEYLYNK-001 is PFS-positive in BRCA non-mutated ovarian cancer, but pembrolizumab alone fails and toxicity rises — Phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 enrolled 1,367 patients with newly diagnosed stage III-IV BRCA1/2 non-mutated epithelial ovarian cancer, and ITT PFS was 22.2 vs 14.6 months with HR 0.71
NICE appraises durvalumab with platinum chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer — NICE Technology Appraisal Guideline TA1190 covers durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer

Full details below ↓

📄 What's Being Published

Manuscripts:

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. — Vergote Ignace et al., Lancet Oncol

1,367 patients were randomly assigned to pembrolizumab-olaparib (n=455), pembrolizumab (n=458), or control (n=454). At the first interim analysis, pembrolizumab-olaparib significantly improved progression-free survival versus control in the CPS ≥10 population (HR 0.63 [95% CI 0.49–0.80]; p<0.0001) and the ITT population (HR 0.68 [0.58–0.81]; p<0.0001), with PFS benefit maintained at the final analysis (median follow-up 49.6 months): HR 0.66 (95% CI 0.53–0.83) in CPS ≥10 and 0.71 (0.61–0.84) in ITT. Pembrolizumab alone remained non-significant versus control in the CPS ≥10 population (HR 0.95 [0.77–1.19]; p=0.33), and grade 3 or higher treatment-related adverse events occurred in 297 (66%) of 452 pembrolizumab-olaparib patients, 255 (56%) of 456 pembrolizumab patients, and 232 (51%) of 454 control patients.

Clinical bottom line: Pembrolizumab plus chemotherapy followed by pembrolizumab-olaparib maintenance delivers a durable PFS gain in BRCA non-mutated stage III–IV ovarian cancer, but with substantially more grade 3+ toxicity and no demonstrated OS advantage, so it is not yet a default first-line choice.

Read full article →

Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial. — Hasegawa Kosei et al., JAMA Oncol

In this exploratory analysis with a median follow-up of 59.1 months (range 52.1–66.5), the overall survival benefit of pembrolizumab plus chemotherapy was sustained in the PD-L1 CPS ≥1 population (median OS 28.6 vs 16.5 months; HR 0.62 [95% CI 0.50–0.76]) and in the ITT population (median OS 26.4 vs 16.8 months; HR 0.64 [95% CI 0.53–0.78]). The progression-free survival advantage was similarly maintained: median 10.5 vs 8.2 months (HR 0.58 [95% CI 0.48–0.71]) in CPS ≥1 and 10.4 vs 8.2 months (HR 0.61 [95% CI 0.51–0.74]) in the ITT population. No new safety signals were observed, and no additional treatment-related deaths occurred since the final analysis.

Clinical bottom line: Five-year follow-up cements pembrolizumab plus platinum-based chemotherapy with or without bevacizumab as the first-line standard for persistent, recurrent, or metastatic cervical cancer, with benefit that holds in both CPS ≥1 and ITT populations.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

KEYNOTE-826 5-year analysis: pembrolizumab plus chemotherapy holds its survival curve separation in advanced cervical cancer

At approximately 5 years, survival benefit with pembrolizumab plus chemotherapy was maintained across both populations: in PD-L1 CPS ≥1, 5-year OS was 33.9% vs 19.7% (median 28.6 vs 16.5 months; HR 0.62) and 5-year PFS was 27.3% vs 9.9% (HR 0.58); in the ITT population, 5-year OS was 33.0% vs 18.1% (HR 0.64) and 5-year PFS was 26.2% vs 9.0% (HR 0.61). The analysis was exploratory and descriptive without prespecified hypothesis testing, but survival curves remained separated throughout long-term follow-up, with a PFS plateau suggesting a subset of long-term responders, and no new safety signals were observed. The central question for clinicians is whether that PFS plateau at 5 years identifies a subset of patients with advanced cervical cancer who can be considered for treatment de-escalation or discontinuation.

Discussed by: @OncoAlert, @JAMAOnc, @jamaoncology.com, @vcclibrary.bsky.social

→ View representative tweet

Sources cited: Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNO… (JAMA Oncol)

KEYLYNK-001 is PFS-positive in BRCA non-mutated ovarian cancer, but pembrolizumab alone fails and toxicity rises

ENGOT-OV43/GOG-3036/KEYLYNK-001 enrolled 1,367 patients with newly diagnosed stage III–IV BRCA1/2 non-mutated epithelial ovarian cancer across 224 gynaecological oncology centres in 22 countries; ITT PFS was 22.2 vs 14.6 months (HR 0.71), and in the PD-L1 CPS ≥10 subgroup, PFS was 23.9 vs 15.2 months (HR 0.66). Pembrolizumab alone did not improve PFS (CPS ≥10 HR 0.95), no overall survival improvement was seen in either pembrolizumab arm, and grade ≥3 treatment-related adverse events occurred in 66% of the pembrolizumab-olaparib group, 56% in the pembrolizumab-alone group, and 51% in the control arm. The central question for oncologists is whether adding immunotherapy to PARP-based maintenance in BRCA non-mutated ovarian cancer justifies a 66% grade ≥3 toxicity rate when no overall survival gain has emerged.

Discussed by: @OncoAlert, @vcclibrary.bsky.social

→ View representative tweet

NICE appraises durvalumab with platinum chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer

NICE Technology Appraisal Guideline TA1190 covers durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer. With this appraisal now in place, clinicians face the question of which untreated advanced or recurrent endometrial cancer patients should receive the olaparib component of the regimen.

Discussed by: @VCCLibrary, @vcclibrary.bsky.social

→ View representative tweet

🔥 Top Ranked Tweets

OncoAlert @OncoAlert

RT @DrRishabhOnco: 🚨 KEYLYNK-001: PFS-positive in BRCA1/2 non-mutated advanced ovarian cancer

Phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 enrolled 1,367 patients with newly diagnosed stage III–IV BRCA1/2 non-mutated epithelial ovarian cancer.

Strategy
Pembrolizumab + chemotherapy
→ pembrolizumab + olaparib maintenance

vs chemotherapy alone.

🔥 Primary endpoint met

ITT population
PFS: 22.2 vs 14.6 months
HR 0.71

PD-L1 CPS ≥10
PFS: 23.9 vs 15.2 months
HR 0.66

But the story is more nuanced.

❌ Pembrolizumab alone did not improve PFS
CPS ≥10: HR 0.95

❌ No overall survival improvement was seen with pembrolizumab–olaparib or pembrolizumab alone.

⚠️ Toxicity

Grade ≥3 treatment-related AEs:

• Pembro + olaparib: 66%
• Pembro alone: 56%
• Control: 51%

Anemia and neutropenia were among the most frequent severe toxicities.

Clinical verdict

A meaningful PFS gain, but at the cost of greater toxicity and without an OS advantage so far.

The key question:

Is adding immunotherapy to PARP-based maintenance truly better than our existing biomarker-driven maintenance strategies?

Promising.
Potentially practice-changing.
But not yet a slam dunk.

@ASCO @oncoalert

#OvarianCancer #GynOnc #Immunotherapy #PARP

🔖 11 ❤️ 27 🔁 11 👁 2,705